Assessment of the Proliferative Marker Ki-67 and P53 Protein Expression in HBV- and HCV-related Hepatocellular Carcinoma Cases in Egypt

Overview

Journal Int J Health Sci (Qassim)

Specialty General Medicine

Date 2011 Apr 9

PMID 21475468

Citations 7

Authors

Waleed S Mohamed

Masoud M Omar

Tarek M Khayri

Ibrahim M Fakhr

Affiliations

Soon will be listed here.

Abstract

Background: Chronic HBV and HCV infections are the major risk factors for the development of HCC through a multistep pathway that involves viral and non-viral dependent pathophysiological steps. Hepatic expression of the nuclear proliferative marker ki-67 and the p53 oncoprotein were found to be associated with poor outcome. So, the present study was done to evaluate the changes in expression of Ki-67 and p53 oncoprotein, and to determine p53 gene mutation in HBV/HCV-related HCC Egyptian patients.

Methods: Eight HBV-and 22 HCV-positive HCC cases have been examined for the presence of p53 mutation by immunohistochemistry (IHC) and single-strand conformation polymorphism (SSCP), followed by direct DNA sequencing. HCV were genotyped by LiPA-II.

Results: Our results have shown that the proliferative marker ki-67 LI and p53 were highly expressed and significantly related to tumor grade in the Egyptian HCC cases (p<0.05). Also, p53 mutation was found in 16 HCC cases by IHC and in 14 HCC cases by SSCP, only 11 patients showed p53 mutation by sequencing. The highest mutation rate was scored for exon 7 (7 mutations) at codon 249; 4 out of 8 (50%) of HBV-related HCC cases and 3 out of 22 (13.6%) of HCV-related HCC cases, followed by exon 5 (3 mutations) at codons 133, 146, 176 in HCV-related HCC cases, then exon 8 at codon 275 in HCV-related HCC cases. The concordance between the IHC and sequencing analysis was 69%.

Conclusion: The present study demonstrates the association between the proliferative marker ki-67 and p53 expression with the tumor grade of Egyptian HBV/HCV-related HCC cases. Our results also support the hypothesis that p53 mutations are rather a late event in the carcinogenesis. Also, they suggest that the final steps of hepatocarcinogenesis are common and independent of the aetiology of the viral infection.

Citing Articles

Prognostic significance of the tumor budding and tumor-infiltrating lymphocytes in survival of hepatocellular carcinoma patients.

Shafiq A, Taha N, Zaky A, Mohammed A, Omran O, Abozaid L Int J Health Sci (Qassim). 2024; 18(6):10-19.

PMID: 39502429 PMC: 11533185.

The Clinical and Prognostic Implications of Pluripotent Stem Cell Markers Expression and Their Correlation with the WNT signal pathway in Hepatocellular Carcinoma.

Osman N, Khalil A, Yousef R Asian Pac J Cancer Prev. 2020; 21(10):2961-2970.

PMID: 33112555 PMC: 7798175. DOI: 10.31557/APJCP.2020.21.10.2961.

Hepatocyte paraffin 1 and arginase-1 are effective panel of markers in HBV-related HCC diagnosis in fine-needle aspiration specimens.

Moudi B, Mahmoudzadeh-Sagheb H, Heidari Z BMC Res Notes. 2020; 13(1):388.

PMID: 32854754 PMC: 7450594. DOI: 10.1186/s13104-020-05230-y.

Reactive Ductules Are Associated With Angiogenesis and Tumor Cell Proliferation in Pediatric Liver Cancer.

Lee S, Zhou P, Gupta A, Shin S Hepatol Commun. 2018; 2(10):1199-1212.

PMID: 30288475 PMC: 6167070. DOI: 10.1002/hep4.1204.

Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity.

Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, Alavian S, Lankarani K, Farrokh P Eur J Histochem. 2018; 62(1):2859.

PMID: 29569872 PMC: 5806503. DOI: 10.4081/ejh.2018.2859.

References

Ng I, Na J, Lai E, Fan S, Ng M . Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1. A comparison with proliferating cell nuclear antigen. Am J Clin Pathol. 1995; 104(3):313-8. DOI: 10.1093/ajcp/104.3.313. View

Khaled H, Bahnassi A, Zekri A, Kassem H, Mokhtar N . Correlation between p53 mutations and HPV in bilharzial bladder cancer. Urol Oncol. 2003; 21(5):334-41. DOI: 10.1016/s1078-1439(03)00014-0. View

El-Kafrawy S, Abdel-Hamid M, El-Daly M, Nada O, Ismail A, Ezzat S . P53 mutations in hepatocellular carcinoma patients in Egypt. Int J Hyg Environ Health. 2005; 208(4):263-70. DOI: 10.1016/j.ijheh.2005.02.002. View

Frank C, Mohamed M, Strickland G, Lavanchy D, Arthur R, Magder L . The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2001; 355(9207):887-91. DOI: 10.1016/s0140-6736(99)06527-7. View

Machida K, Cheng K, Sung V, Shimodaira S, Lindsay K, Levine A . Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A. 2004; 101(12):4262-7. PMC: 384729. DOI: 10.1073/pnas.0303971101. View

Pellin A, Blesa R, Adrados M, Llombart-Bosch A . Absence of p53 gene mutations in hepatocarcinomas from a Mediterranean area of Spain. A study of 129 archival tumour samples. Virchows Arch. 1999; 434(6):497-501. DOI: 10.1007/s004280050374. View

Mitsumoto Y, Nakajima T, Marutani M, Kashiwazaki H, Moriguchi M, Kimura H . Loss of p53 transcriptional activity in hepatocellular carcinoma evaluated by yeast-based functional assay: comparison with p53 immunohistochemistry. Hum Pathol. 2004; 35(3):350-6. DOI: 10.1016/j.humpath.2003.09.014. View

Li D, Cao Y, He L, Wang N, Gu J . Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis. 1993; 14(2):169-73. DOI: 10.1093/carcin/14.2.169. View

Zekri A, Mohamed W, Samra M, Sherif G, El-Shehaby A, El-Sayed M . Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol. 2004; 13(4):305-11. DOI: 10.1016/j.trim.2004.10.001. View

10.

Wong N, Lai P, Lee S, Fan S, Pang E, Liew C . Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol. 1999; 154(1):37-43. PMC: 1853447. DOI: 10.1016/S0002-9440(10)65248-0. View

11.

Lee S, Park C, Sung C, Choi J, Oh Y, Cho J . Correlation of mutation and immunohistochemistry of p53 in hepatocellular carcinomas in Korean people. J Korean Med Sci. 2002; 17(6):801-5. PMC: 3054961. DOI: 10.3346/jkms.2002.17.6.801. View

12.

Zekri A, Bahnassy A, Madbouly M, Asaad N, El-Shehaby A, Alam El Din H . p53 mutation in HCV-genotype-4 associated hepatocellular carcinoma in Egyptian patients. J Egypt Natl Canc Inst. 2007; 18(1):17-29. View

13.

Matsubara K, Tokino T . Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med. 1990; 7(3):243-60. View

14.

Nakamoto Y, Guidotti L, Kuhlen C, Fowler P, Chisari F . Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 1998; 188(2):341-50. PMC: 2212453. DOI: 10.1084/jem.188.2.341. View

15.

Koskinas J, Petraki K, Kavantzas N, Rapti I, Kountouras D, Hadziyannis S . Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma. J Viral Hepat. 2005; 12(6):635-41. DOI: 10.1111/j.1365-2893.2005.00635.x. View

16.

Idilman R, de Maria N, Colantoni A, Van Thiel D . Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepat. 1998; 5(5):285-99. DOI: 10.1046/j.1365-2893.1998.00116.x. View

17.

Sheen I, Jeng K, Wu J . Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?. World J Gastroenterol. 2003; 9(6):1202-7. PMC: 4611784. DOI: 10.3748/wjg.v9.i6.1202. View

18.

Chen Ban K, Singh H, Krishnan R, Seow H . Comparison of the expression of beta-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1. J Surg Oncol. 2004; 86(3):157-63. DOI: 10.1002/jso.20051. View

19.

Bressac B, Kew M, Wands J, Ozturk M . Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991; 350(6317):429-31. DOI: 10.1038/350429a0. View

20.

Ito Y, Matsuura N, Sakon M, Takeda T, Umeshita K, Nagano H . Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer. 1999; 81(4):747-51. PMC: 2362905. DOI: 10.1038/sj.bjc.6690758. View